CLINICAL_TRIALS
trial_result
· 2025-06-27
Clinical Trial Update: Cough Reduction in IPF With Nalbuphine ER [Phase 2]
Summary
Trevi Therapeutics completed a Phase 2 trial of nalbuphine extended-release for cough reduction in idiopathic pulmonary fibrosis.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Trevi Therapeutics | Conditions: Idiopathic Pulmonary Fibrosis | Phase 2 | Status: COMPLETED